Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Edison Is Sponsoring a Call To Discuss the Evolving AML Landscape

Ticker(s): JAZZ, ATNM, NVS, ABBV, SGEN, CELG, AGIO

Who's the expert?

Name: Dr Douglas Smith - MD

Institution: Johns Hopkins University

Bio:

  • Involved in the care of several hundred patients with AML at various stages of treatment (active and follow-up) and include newly diagnosed pts, relapsed, refractory, pre and post BMT
  • Manages the leukemia clinical trials portfolio for AML for John Hopkin's large academic practice
  • Confirmed very strong knowledge of clinical data for AML treatments

Interview Questions
Q1.

Please describe your clinical practice and development experience as it relates to AML.

Added By: joe_mccann
Q2.

What pipeline products do you think are most likely to change the treatment paradigm for AML?

Added By: joe_mccann
Q3.

What impact will Vyxeos have on how you treat patients?

Added By: joe_mccann
Q4.

What specific subgroups within AML are those that have the greatest unmet medical need?

Added By: joe_mccann
Q5.

How do you see MRD evolving in AML and what role do you anticipate it will play in the next 3-5 years?

Added By: userda0312f6
Q6.

What do you estimate is the % of patient with AML who receive 7+3 (or other aggressive regimen) vs. HMA or low dose cytarabine?

Added By: userda0312f6

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.